Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) Overview 6
Therapeutics Development 7
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Stage of Development 7
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Therapy Area 8
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Indication 9
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Companies 12
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Companies Involved in Therapeutics Development 20
A. Menarini Industrie Farmaceutiche Riunite Srl 20
AlbireoPharma 21
Takeda Pharmaceutical Company Limited 22
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Drug Profiles 23
A-3914 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
A-5425 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DTI-100 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ibodutant - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
nepadutant - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Antagonize NK 1 and NK 2 Receptors for Pain - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
TAK-480 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Dormant Projects 30
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Discontinued Products 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 20
Pipeline by AlbireoPharma, H1 2016 21
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 22
Dormant Projects, H1 2016 30
Discontinued Products, H1 2016 31

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Mechanism of Actions, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 18